Topical problems of antiviral therapy for chronic hepatitis C

Full Text

Abstract

Antiviral therapy using interferon-free regimens for chronic hepatitis C (CHC) is being more frequently practiced by hepatologists due to the high efficiency of a short treatment cycle and the lowest rate of adverse events. The review discusses the most topical problems that will present themselves in practicing hematologists when treating patients with CHC under the present-day conditions. The use of direct-acting antiviral drugs requires knowledge and skills for physicians to orient themselves in the list of these drugs to create their based regimens, the efficiency and safety of which are proven in the context of evidence-based medicine. The review gives data on the efficiency and safety of 3D therapy for CHC according to the baseline characteristics of patients.

About the authors

I G Bakulin

References

  1. Ponziani F, Gasbarrini A, Pompili M, Burra P, Fagiuoli S. Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview. Transplant Proc. 2011;43(1): 291-295. doi: 10.1016/j.transproceed.2010.09.102.
  2. Bakulin I, Pasechnikov V, Varlamicheva A, Sannikova I. NS3-protease inhibitors for treatment of chronic hepatitis C: efficacy and safety. World J Hepatol. 2014;6(5):326-339. doi:10.4254 /wjh.v6.i5.326.
  3. Бакулин И.Г. Можно ли говорить о смене парадигмы при лечении хронического гепатита? Эффективная фармакотерапия. 2014;7:36-40.
  4. EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2015;63:199-236. doi: 10.1016/j.jhep.2015.03.025.
  5. Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D, Weiland O, Aguilar H, Xion J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370:1594-1603. doi: 10.1056/nejmoa1315722.
  6. Zeuzem S, Jacobson I, Baykal T, Marinho R, Poordad F, Bourlière M, Sulkowski M, Wedemeyer H, Tam E, Desmond P, Jensen D, Di Bisceglie A, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki Τ, Bernstein B. Retreatment of HCV with ABT-450/r—Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med. 2014;370:1604-1614. doi: 10.1056/nejmoa1401561.
  7. Andreone P, Colombo M, Enejosa J, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink H, Rodrigues L, Hu Y, Podsadecki T, Bernstein B. ABT-450, Ritonavir, Ombitasvir, and Dasabuvir achieves 97% and 100% sustained virologic response with or without Ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365. doi.org/10.1053/j.gastro.2014.04.045.
  8. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Rui T, Marinho R, Tsai N, Nyberg A, Box T,Younes Z, Enayati P, Green S, Baruch Y, Bhandari B, Caruntu F, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki Τ, Reddy K. ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med. 2014;370:1983-1992. doi:10.1056 /nejmoa1402338.
  9. Poordad F, Hezode C, Trinh R, Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K, Shiffman M, Wedemeyer H, Berg T, Yoshida E, Forns X, Lovell S, Da Silva-Tillmann B, Collins C, Campbell A, Podsadecki. TURQUOISE-II: SVR12 rates of 92—96% in 380 hepatitis C virus genotype 1-infected adults with compensated cirrhosis treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV). J Hepatol. 2014;60:(Issue 1):523. doi: 10.1016/s0168-8278(14)61458-6.
  10. Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K, Shiffman M, Wedemeyer H, Berg T, Yoshida E, Forns X, Lovell S, Da Silva-Tillmann B, Collins C, Campbell A, Podsadecki Τ, Bernstein B. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med. 2014;370:1973-1982. doi: 10.1056/nejmoa1402869.
  11. Pockros P, Reddy K, Mantry P, Cohen E, Bennett M, Sulkowski M, Bernstein D, Podsadecki T, Cohen D, Shulman N, Wang D, Khatri A, Abunimeh M, Lawitz E. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV Gt1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. J Hepatol. 2015;62:257. doi: 10.1016/s0168-8278(15)30147-1.

Statistics

Views

Abstract: 96

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2015 Bakulin I.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies